A B S T R A C T Metabolic clearance (MCR) and production rates (PR) of human thyrotropin (hTSH) were determined by the constant infusion to equilibrium method 57 times in 55 patients. 16 control patients had a mean hTSH MCR of 50.7 ml/min. The mean hTSH MCR was significantly (P < 0.02) higher in 19 euthyroid men (51.6 ml/min) than in 12 euthyroid women (43.0 ml/min), but this apparent sex difference disappeared when the MCR were corrected for surface area, 25.8 (men) versus 25.2 ml/min per m' (women). Hypothyroid patients had significantly (P < 0.005) lower hTSH MCR (30.9 ml/min), and hyperthyroid patients had significantly (P < 0.05) higher hTSH MCR (60.9 ml/min) than controls. The hTSH MCR in patients with "decreased thyroid reserve" (40.9 ml/ min), hyperfunctioning thyroid nodule (53.8 ml/min), and "empty sella syndrome" (46.6 ml/min) were not significantly different from controls. The mean hTSH PR in controls (104.3 mU/day) was significantly (P < 0.005) different from that in patients with "decreased thyroid reserve" (956 mU/day), hypothyroidism (4,440 mU/day), hyperthyroidism (< 43.9 mU/ day) and a hyperfunctioning thyroid nodule (<38.7 mU/day). In primary hypothyroidism intravenous triiodothyronine therapy (50 pg/day) for 10 days decreased the hTSH PR (from 4,244 to 2,461 mU/day) before changes in the hTSH MCR (from 33.1 to 33.7 mU/day) were observed.
INTRODUCTION
The introduction of methods for measuring human thyrotropin (hTSH) 1 in serum (1) (2) (3) (4) (5) have made it possible to define the thyroid and pituitary interrelationships in various thyroid disorders. However, despite the common use of the serum hTSH concentration, little information exists on metabolic clearance rates (MCR) and production rates (PR) of hTSH in health and disease. In 1962, Bakke, Lawrence, and Roy (6) administered bovine TSH intravenously to euthyroid and hypothyroid patients, determined the half-life of the serum bTSH by bioassay, and estimated production rates of hTSH to be 260 USP mU/day in the former and approximately 2,600 USP mU/day in the latter. In 1967, Odell, Utiger, Wilber, and Condliffe (7) injected ['I]hTSH intravenously as a single bolus in tracer quantities and followed the disappearance of labeled hormone by antibody precipitation. MCR were 42.5 ml/min in euthyroid and 36.3 ml/min in hypothyroid patients. The calculated hTSH production rates were 165.2 mU/day and 1,033.1 mU/day. respectively, in terms of human TSH reference standard A. In 1971, Beckers, Machiels, Soyez, and Cornette (8) utilized a similar single injection technique and found no statistically significant difference in the MCR of euthyroid (56.2 ml/min), hyperthyroid (60.6 ml/min), or hypothyroid (62.8 ml/min) patients. Furthermore, the calculated production rates in this study suggested that hyperthyroid patients had higher production rates of hTSH (517.2 mU/day) than euthvroid patients (419.1 mU/day).
In an attempt to elucidate this probilem further and to resolve these discrepancies, we have measured the 1Abbreviations used in this paper: hTSH, human thyrotropin; M.CR, metabolic clearance rates; PR, production rates, RaI, radioiodine; T4, thyroxine; T,R, triiodothyronine resin uptake; TT3, total triiodothyronine; TT4, total thyroxine. MCR of hTSH in various thyroid disorders by means of the constant infusion to equilibrium method of Tait (9) . Further, we have measured the endogenous hTSH concentration and calculated its PR using a sensitive radioimmunoassay capable of differentiating normal from low hTSH levels in unconcentrated sera (5) . IACi/,ug by the method of Hunter and Greenwood (10) . Immediately after iodination the ['31I]hTSH was separated from aggregated products of iodination and inorganic iodide on a G-100 Sephadex column (1.5 X 90 cm). Approximately 0.25-1.0 ug uCi) Patients. There were 31 patients who were clinically euthyroid. 16 of these patients had no history of thyroid or pituitary disease and normal levels of total thyroxine (TT4), free thyroxine (free T4), total triiodothyronine (TTs), Ta resin uptake (T8R), RaI uptakes, and hTSH. The circulating levels of TT4, free T4, and TT3 were all performed by competitive protein binding assays and equilibrium dialysis techniques (5) .
METHODS
The 16 patients included 10 men and six women and served as the control group. The other 15 patients, judged to be clinically euthyroid, had historical evidence of either thyroid or pituitary disease but had normal levels of TT4, free T4, and TTs, and T3R. These 15 patients were specifically included to provide a greater number of MCR determinations in patients with normal levels of circulating thyroid hormones and included the following: four patients with the empty sella syndrome documented by pneumoencephalography who were taking no therapy; four patients with a hyperfunctioning thyroid nodule, and seven (7, 8) .
Our studies suggest that it may be more appropriate to express MCR as ml/min per m2 (see Fig. 2 (Table II) . Correlation of hTSH MCR with serum thyroid hor0one concentration and creatinine clearance. The MCR and MCR/m2 of hTSH of all patients were related to the serum TT4 concentration with correlation coefficients r = 0.476, P < 0.001, and r = 0.534, P < 0.001, respectively (Fig. 3) . The MCR of hTSH of all patients was also related to the serum TT3 concentration with a correlation coefficient r = 0.537, P < 0.001. Likewise the MCR was related to the endogenous creatinine clearance with a correlation coefficient r= 0.609, P < 0.001 (Fig. 4) patients the PR was 4440±3732 mU/day or 2767±2278 nU/day per m2 (P < 0.001), while in hyperthyroid patients the PR was undetectable (< 43.9±3.5, P < 0.005). The PR was also undetectable in patients with single hyperfunctioning thyroid nodules. In the patients with the empty sella syndrome, the PR was in the normal range at 119±51 mU/day or 63±28 mU/ day per m2. The patients with decreased thyroid reserve require detailed comment and specific characterization. The clinical data of these six patients are presented in Table III . There were two men (ages 41 and 65) and four women (ages 46-60). The serum TT4 ranged from 4.0 to 6.0 lAg/100 ml, the free T4 varied from 0.8 to 1.1 ng/100 ml, the TT3 ranged from 120 to 195 ng/100 ml, the RaI uptake ranged from 14 to 20%, and the basal metabolic rate varied from -19 to + 10%. The TaR was low-normal in all, suggesting no abnormality in the serum thyroxine-binding proteins. The basal serum hTSH was elevated in each patient and ranged from 6.2 to 41.0 AsU/ml, with five of the six patients having serum hTSH concentrations of 16.5 iAU/ml or less. Five of the six had a blunted rise in the RaI uptake and TT4 after bTSH administration for 3 days. The hTSH response to the intravenous administration of a single bolus of 200 lAg of TRH (5) was abnormal with peak concentrations of hTSH varying from 44 to 150 /AU/ml. In all of these patients, the mean PR was approximately nine times normal at 956±622 mU/d or 544±342 mU/day per m'.
In patients with either decreased thyroid reserve or primary hypothyroidism, the elevated serum hTSH concentration was found to be related to an increased hTSH PR with a correlation coefficient r = 0.93, P <0.001 (Fig. 5) .
Effect of acute thyroid hormone replacement. Acute triiodothyronine therapy (50 iAg intravenously for 10 days) in five hypothyroid patients produced no signifi- TT4 and triiodothyronine concentration and the MCR hTSH. Previous workers had also shown that the clearance rate of TSH injected into animals was dependent on the metabolic state of the animal but unrelated to the presence of thyroid tissue per se (13, 14) . The exact sites of clearance of hTSH have not been resolved. We have recently studied the clearance of ['1I]hTSH in the dog and shown that significant clearance occurred only in the kidney and not in the liver, thyroid, or femoral muscle.' These data are supported by the present study, which demonstrated a significant (P < 0.001) correlation between the endogenous creatinine clearance and MCR of hTSH, and agree with the observation that patients with renal insufficiency had reduced MCR of hTSH (8) . Whether clearance by the kidney involves degradation' or excretion is unknown. Previous studies (15, 16) have shown bioassayable thyroid-stimulating substances in the urine of myxedematous and some normal subjects suggesting that hTSH, like other glycoproteins, is partially excreted into the urine in a biologically active form.
The calculation of the hTSH PR from the observed hTSH MCR depends on an accurate measurement of the serum concentration of endogenous hTSH and the assumption that the endogenous hTSH concentration remains constant for the 24-h period. Accurate determinations of endogenous hTSH have been possible in primary hypothyroidism, but precise distinctions between normal and hyperthyroid patients have only recently been reported (4, 5) . These newer methods have utilized nonequilibrium conditions, highly purified labeled hTSH, higher dilutions of sera, and incubation pf standards in "TSH-free" serum. These methods permit differentiation of hTSH concentrations in normal and hyperthyroid patients and yield lower values for normal serum hTSH than had previously (7, 8) been used for calculation of the hTSH PR. Further, the assumption that the 24 h production rate of hTSH remains constant has been supported by studies showing constant blood levels of hTSH during the 24-h period (3, 17, 18) . However, more recent studies (19, 20) utilizing sensitive radioimmunoassays have demonstrated a significant small and brief rise in hTSH concentra- tion in the early morning hours, suggesting a circadian variation in TSH production. Thus the results in the present study, which assumes constant production of hTSH, may be slightly low since this method does not include the brief rise of hTSH during the early morning hours. The mean calculated hTSH PR for control subjects observed in the present study was lower than that reported by Odell et al. (7) or Beckers et al. (8) . Since the hTSH MCR in these three studies were similar, the disparity in hTSH PR was due to the higher endogenous serum hTSH concentrations found in the control patients of the previous investigators. Odell et al. (7) used a radioimmunoassay in wvhich serum was first concentrated in order to detect normal levels, whereas Beckers et al. (8) were not able to distinguish normal from hyperthyroid hTSH serum concentrations. The data of the latter investigators (8) suggested that the hTSH PR in hyperthyroidism was slightly higher than that in normal patients. The present study clearly demonstrated that hyperthyroid patients have hTSH PR that are lower than northal patients. Further, patients with hyperfunctioning thyroid nodules had undetectable hTSH PR that could not be distinguished from classical hyperthyroid patients. Nevertheless, further refinement of the hTSH assay may detect subtle differences in the hTSH serum concentrations and PR in these two disorders similar to that found for ACTH production in the single adrenal adenoma versus adrenal hyperplasia in Cushing's disease (21) .
Patients with primary hypothyroidism or decreased thyroid reserve had elevated serum concentrations and production rates of hTSH. Although a small part of the elevated serum hTSH concentrations in these two disorders was related to delayed clearance, the major determinant was an accelerated PR. For the first time, this study has demonstrated that an elevated serum hTSH level was related to an elevated PR of hTSH throughout the spectrum of primary thyroidal failure. Furthermore, acute treatment of five hypothyroid patients with intravenous triiodothyronine for 10 days decreased the hTSH PR and serum concentrations before significant changes were observed in the hTSH MCR, suggesting that the acute changes in serum TSH concentrations resulted from central pituitary inhibition before peripheral clearance of hTSH was altered.
The patients with decreased thyroid reserve had elevated serum concentrations and PR of hTSH, clearly demonstrating that although such patients appear clinically euthyroid, their pituitary glands are secreting more hTSH than normal. Thus, these patients were probably secreting less thyroid hormone than -was normal for their individual metabolic requirements, and the increase in pituitary hTSH secretion may be an early and very sensitive indicator of subtle pritnary thyroid failure. The importance of slight but significantly elevated serum hTSH concentrations requires thorough investigation, since the consequence of this subclinical metabolic state on the growth and function of the pituitary and on hTSH and other pituitary hormones may have important implications.
In conclusion, these studies on patients with a variety of thyroid disorders showed that the primary determinant of the serum hTSH concentration is the pituitary hTSH secretion rate rather than its MCR. Although a highly significant relationship exists between the hTSH clearance rate and the serum concentration of thyroxine and triiodothyronine, the changes in the hTSH clearance rate in various thyroid disorders are less than and may occur later than changes in the hTSH secretion rate.
